Trial Profile
Phase I/Ib Trial of Radiotherapy in Combination With Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Head and neck cancer; Mouth neoplasm; Squamous cell cancer
- Focus Adverse reactions
- 21 Jan 2022 Planned End Date changed from 19 May 2022 to 19 May 2024.
- 21 Jan 2022 Planned primary completion date changed from 25 Jun 2021 to 19 May 2023.
- 19 May 2021 Planned End Date changed from 25 Jun 2021 to 19 May 2022.